Zacks Research Has Bullish Estimate for Exelixis Q4 Earnings

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities researchers at Zacks Research boosted their Q4 2024 EPS estimates for shares of Exelixis in a research report issued on Monday, December 16th. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will earn $0.37 per share for the quarter, up from their prior forecast of $0.36. The consensus estimate for Exelixis' current full-year earnings is $1.69 per share. Zacks Research also issued estimates for Exelixis' Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.57 EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.49 EPS and FY2026 earnings at $2.14 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. The business had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. Exelixis's revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 earnings per share.

A number of other equities analysts have also weighed in on EXEL. UBS Group initiated coverage on shares of Exelixis in a research report on Thursday, September 19th. They set a "neutral" rating and a $30.00 target price for the company. Piper Sandler raised their price objective on shares of Exelixis from $33.00 to $36.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. TD Cowen boosted their target price on shares of Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a report on Monday, October 21st. HC Wainwright restated a "buy" rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $34.00 price target on shares of Exelixis in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $31.88.

Exelixis Trading Up 0.1 %

Shares of EXEL stock traded up $0.02 on Thursday, hitting $33.68. 2,835,642 shares of the stock were exchanged, compared to its average volume of 2,059,595. Exelixis has a one year low of $19.20 and a one year high of $36.97. The firm's 50 day moving average is $33.36 and its two-hundred day moving average is $27.47. The firm has a market capitalization of $9.62 billion, a PE ratio of 21.59, a P/E/G ratio of 0.89 and a beta of 0.52.

Institutional Investors Weigh In On Exelixis

A number of hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC lifted its position in Exelixis by 45.3% in the second quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company's stock valued at $2,031,000 after purchasing an additional 28,126 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company's stock worth $608,993,000 after purchasing an additional 424,000 shares during the last quarter. Seizert Capital Partners LLC increased its stake in shares of Exelixis by 8.0% in the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company's stock worth $12,195,000 after buying an additional 34,875 shares during the period. Los Angeles Capital Management LLC raised its holdings in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock valued at $46,473,000 after buying an additional 991,494 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Exelixis by 60.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company's stock valued at $1,424,000 after buying an additional 20,641 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Transactions at Exelixis

In related news, EVP Patrick J. Haley sold 10,000 shares of the business's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares in the company, valued at $9,828,514.55. The trade was a 3.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total transaction of $659,500.00. Following the transaction, the executive vice president now owns 605,325 shares in the company, valued at $15,968,473.50. The trade was a 3.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 339,736 shares of company stock valued at $11,508,610 in the last quarter. Insiders own 2.85% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.